申请人:Shijiazhuang Sagacity New Drug
Development Co., Ltd.
公开号:EP3492465A1
公开(公告)日:2019-06-05
The present invention relates to a class of tricyclic compounds and an application thereof as a sphingosine 1-phosphate type 1 (S1P1) receptor agonist. The invention specifically relates to a compound represented by formula (II), and a tautomer and pharmaceutically acceptable salt of same.
本发明涉及一类三环化合物及其作为 1 型鞘磷脂(S1P1)受体激动剂的应用。本发明具体涉及由式(II)代表的化合物及其同系物和药学上可接受的盐。